close

Agreements

Date: 2018-05-29

Type of information: Nomination

Compound:

Company: BioNTech (Germany)

Therapeutic area: Cancer - Oncology - Infectious diseases

Type agreement: nomination

Action mechanism:

Disease:

Details:

  • • On May 29, 2018, BioNTech AG, a fully-integrated biotechnology company pioneeringindividualized cancer immunotherapy, announced the appointment of Özlem Türeci, M.D., as Chief Medical Officer, effective June 1, 2018. Dr. Türeci has chaired BioNTech´s Scientific and Clinical Advisory Board since the inception of the company. Dr. Türeci has over 25 years of experience in cancer research and immuno-oncology, specifically in the identification of immunotherapeutic drug targets and the development of antibodies, as well as vaccine-based therapies. In 2001, Dr. Türeci co-founded Ganymed Pharmaceuticals as Chief Scientific Officer and became its Chief Executive Officer in 2008. Ganymed Pharmaceuticals, which focused on developing anew generation of first-in-class antibodies in solid cancers, was sold to Astellas Pharma for €422million in 2016. Dr. Türeci is chairman and co-initiator of Ci3, the German Cluster Initiative of Individualized ImmunIntervention (Ci3) based in Mainz, Germany. She is also an executive board member of the Association for Cancer Immunotherapy (CIMT). She authored over 110 peer-reviewedpublications and is an inventor on more than 80 patents and patent applications.

Financial terms:

Latest news:

Is general: Yes